A99 COST-EFFECTIVENESS OF FIRST-LINE BIOLOGICS FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS
A99 一线生物制剂治疗中重度溃疡性结肠炎的成本效益
期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-023-01041-8
Zhang, Jinsui; Xia, Zemin; Guo, Wanjie; Ren, Xiaoxiao; Liu, Fang; Ratnaparkhi, Gargi; Pagada, Amit; Subramanian, Subhashini; Hu, Min; Chen, Wen; Beilman, C L; Fedorak, R; Halloran, B
